Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings per share of ($0.53) for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.64). Intellia Therapeutics posted earnings per share of ($0.43) in the same quarter last year, which suggests a negative year-over-year growth rate of 23.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.31) to ($1.97). For the next year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($3.00) to ($1.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.12. The firm had revenue of $10.60 million for the quarter, compared to analyst estimates of $9.17 million. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company’s revenue was up 43.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) EPS.
Several equities research analysts have recently weighed in on the company. Raymond James raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital set a $57.50 target price on shares of Intellia Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 27th. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Zacks Investment Research raised shares of Intellia Therapeutics from a “hold” rating to a “strong-buy” rating and set a $15.00 price target for the company in a report on Wednesday, November 6th. Finally, ValuEngine lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $25.21.
Shares of NTLA stock traded down $0.13 during trading hours on Friday, reaching $17.10. 606,847 shares of the company’s stock were exchanged, compared to its average volume of 575,467. Intellia Therapeutics has a fifty-two week low of $10.26 and a fifty-two week high of $19.00. The stock has a market capitalization of $835.88 million, a P/E ratio of -8.64 and a beta of 2.84. The business has a fifty day moving average price of $13.84 and a 200-day moving average price of $14.78. The company has a quick ratio of 7.89, a current ratio of 7.89 and a debt-to-equity ratio of 0.05.
Institutional investors have recently bought and sold shares of the business. Benjamin Edwards Inc. lifted its holdings in shares of Intellia Therapeutics by 60.9% during the 2nd quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after acquiring an additional 640 shares during the period. Janney Montgomery Scott LLC raised its position in Intellia Therapeutics by 3.9% in the second quarter. Janney Montgomery Scott LLC now owns 32,185 shares of the company’s stock worth $527,000 after purchasing an additional 1,202 shares in the last quarter. HighTower Advisors LLC raised its position in Intellia Therapeutics by 5.3% in the second quarter. HighTower Advisors LLC now owns 36,437 shares of the company’s stock worth $598,000 after purchasing an additional 1,826 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Intellia Therapeutics by 23.4% during the second quarter. JPMorgan Chase & Co. now owns 10,000 shares of the company’s stock worth $152,000 after purchasing an additional 1,894 shares during the period. Finally, Bank of Montreal Can lifted its stake in Intellia Therapeutics by 406.5% during the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after purchasing an additional 3,069 shares during the period. 89.92% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Recommended Story: How Do Tariffs Affect Trade Balances?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.